{
    "root": "389f8557-7dbc-40ac-8b68-e8e1a83f6325",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Plerixafor",
    "value": "20240101",
    "ingredients": [
        {
            "name": "PLERIXAFOR",
            "code": "S915P5499N"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "plerixafor injection indicated combination filgrastim mobilize hematopoietic stem cells ( hscs ) peripheral blood collection subsequent autologous transplantation patients non-hodgkin ’ lymphoma ( nhl ) multiple myeloma ( mm ) .",
    "contraindications": "initiate plerixafor injection treatment patient received filgrastim daily 4 days . ( 2.1 ) repeat plerixafor injection dose 4 consecutive days . ( 2.1 ) dose based patient weight less equal 83 kg : 20 mg dose select dose based 0.24 mg/kg actual body weight . ( 2.1 ) greater 83 kg : select dose based 0.24 mg/kg actual body weight . ( 2.1 ) administer subcutaneous injection approximately 11 hours prior initiation apheresis . ( 2.1 ) renal impairment : creatinine clearance ≤50 ml/min , decrease dose one-third 0.16 mg/kg . ( 2.3 )",
    "warningsAndPrecautions": "plerixafor injection 24 mg/1.2 ml ( 20 mg/ml ) sterile , preservative-free , clear , colorless pale-yellow solution supplied clear glass single-dose vial . ndc number : 0480-4320-01 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86° f ) [ usp controlled room temperature ] .",
    "adverseReactions": "plerixafor injection contraindicated patients history hypersensitivity plerixafor [ ( 5.1 ) ] . anaphylactic shock occurred plerixafor injection .",
    "indications_original": "Plerixafor Injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).",
    "contraindications_original": "Initiate Plerixafor Injection treatment after the patient has received filgrastim once daily for 4 days. ( 2.1 ) Repeat Plerixafor Injection dose up to 4 consecutive days. ( 2.1 ) Dose based on patient weight Less than or equal to 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) greater than 83 kg: select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis. ( 2.1 ) Renal impairment: If creatinine clearance is ≤50 mL/min, decrease dose by one-third to 0.16 mg/kg. ( 2.3 )",
    "warningsAndPrecautions_original": "Plerixafor Injection 24 mg/1.2 mL (20 mg/mL) is a sterile, preservative-free, clear, colorless to pale-yellow solution supplied in a clear glass single-dose vial.\n                  NDC Number: 0480-4320-01\n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86° F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Plerixafor Injection is contraindicated in patients with a history of hypersensitivity to plerixafor [see Warnings and Precautions (5.1)]. Anaphylactic shock has occurred with use of Plerixafor Injection."
}